RLMD · Relmada Therapeutics, Inc.
$4.80
+0.05 (+1.05%)
At close · Aug 14
Market Cap
$512.02M
Shares
106.67M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Paul Kelly | Chief Operating Officer | Appointed | 2025-01-06 |
| Eric Schmidt | member of the Board of Directors | Resigned | 2023-09-06 |
| Sergio Traversa | Class II Director | Appointed | 2023-05-25 |
| Charles J. Casamento | Class II Director | Appointed | 2023-05-25 |
| Fabiana Fedeli | Class I director | Appointed | 2023-01-17 |
| Eric Schmidt | Class I Director | Appointed | 2022-06-01 |
Key facts
CIK
1553643
CUSIP
75955J402
13F (30d)
126 filings
124 filers
Visit website
Investor relations